Treatment of CHF or hypertension (in combination with thiazide or loop diuretics) and diuretic-induced hypokalemia.
Reduction of lithium-induced polyuria; slowed reduction of pulmonary function in patients with cystic fibrosis (aerosol form).
Adult: PO 5 to 10 mg/day.
Lithium-Induced Polyuria PO 10 to 20 mg/day.
Cystic Fibrosis Dissolve in 0.3% saline and deliver by nebulizer.
Interferes with sodium reabsorption at distal tubule, resulting in increased excretion of water and sodium and decreased excretion of potassium.
Serum potassium more than 5.5 mEq/L; potassium supplementation; impaired renal function: spironolactone or triamterene therapy.
Use Cautiously in:
CV: Angina pectoris; orthostatic hypotension; arrhythmia.
CNS: Headache; dizziness; encephalopathy; paresthesia; tremors; vertigo; nervousness; mental confusion; insomnia; decreased libido; depression.
DERM: Skin rash; itching; pruritus.
EENT: Visual disturbances; tinnitus; nasal congestion.
GI: Nausea; anorexia; diarrhea; vomiting; abdominal pain; gas pain; appetite changes; constipation; GI bleeding; abdominal fullness; thirst; dry mouth; heartburn; flatulence.
GU: Impotence; polyuria; dysuria; urinary frequency.
HEMA: Aplastic anemia; neutropenia.
METAB: Increased serum potassium levels.
RESP: Cough; dyspnea.
OTHER: Musculoskeletal (eg, weakness; fatigue; muscle cramps; joint/back/chest pain; neck or shoulder ache).
Angiotensin-converting enzyme inhibitors
May result in severely elevated serum potassium levels.
May severely increase serum potassium levels, possibly resulting in cardiac arrhythmias or cardiac arrest. Do not administer to patients taking potassium preparations.
Therapeutic Classification: diuretics, potassium-sparing diuretics
Absorption: 30–90% absorbed.
Distribution: Widely distributed.
Metabolism/Excretion: 50% eliminated unchanged in urine, 40% excreted in the feces.
Half-life: 6–9 hr.
SINGLE DOSE ONSET 2 HOUR
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal